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ABSTRACT 
 
Characterization of a Gene Abundantly Expressed in Stallion Testis.  
(December 2010) 
Jordan Elizabeth Shields, B.S., Valdosta State University 
Chair of Advisory Committee: Dr. Penny K. Riggs 
 
 NMES1 is a gene of unknown function first characterized in 2002.  Reduction of 
the expression of this gene has been implicated in skin tumorigenesis in mice.  
Expression of NMES1 is observed in epithelial tissue but expression in the testis is 
significantly higher than in epidermis.  Because stallion fertility is an economically 
important trait, we decided to characterize the NMES1 gene in stallions.  We screened 
the CHORI241 library and obtained the full length equine NMES1 genomic sequence by 
direct sequencing off of clone CH241-11J8.   In order to experimentally determine the 5’ 
and 3’ untranslated regions (UTRs) we conducted RLM-RACE experiments using 
stallion testis RNA.   The equine NMES1 mRNA is 534 nt long and contains 5 exons.   
Fluorescence in situ hybridization mapped NMES1 to chromosome Eca1q23.    In 
situ experiments to testis tissue sections were inconclusive and yielded no data 
confirming the physical expression pattern of NMES1 in stallion testis tissue.    
In order to determine the expression pattern of NMES1 mRNA we conducted 
qRT-PCR assays on a panel of stallion testis samples from horses with normal and 
abnormal fertility.  We found that expression was variable among both groups, with 
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significantly less expression in some individuals.  We also conducted the qRT-PCR 
assay on a panel of five equine tissues and found that the expression of NMES1 was 
more than 100-fold greater in testis than in other tissues examined.    
miR-147b is a miRNA of unknown target found within the 3’ UTR of NMES1.  
We conducted a miRNA qRT-PCR assay to determine the expression levels in stallion 
testis samples from fertile and sub-fertile stallions.   We observed similar expression 
among both groups and the ratio of mRNA to miRNA did not appear constant.  We also 
investigated miR-147b expression in a panel of five equine tissues and found that equine 
spleen had more than 8-fold greater expression than testis.     
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1. INTRODUCTION  
 
 The NMES1 gene was first identified in humans and is predicted to encode a relatively 
small protein (83 amino acids)of unknown function (Zhou et al. 2002).   Although it was 
originally named NMES1 after being discovered as a transcript identified as normal mucosa of 
the esophagus specific 1, current symbols for this gene are C15orf48 (human) and AA467197 
(mouse). No consistent name currently exists for this gene. For simplicity, the gene will be 
referred to as NMES1 in the remainder of the document.  Previous experiments showed that 
NMES1 was expressed abundantly in adult mouse testis, at a level 50 times greater than all other 
tissues examined (Riggs et al. unpublished).  A microRNA (miRNA) has also been identified 
within the 3’ UTR of the mouse Nmes1 gene (Landgraf et al. 2007).  The presence of the miRNA 
was computationally verified in Equus caballus as well (Zhou et al. 2009).  This miRNA is 
identified as miR-147 in the mouse, but both the human and equine microRNA is labeled miR-
147b.  
Because NMES1 transcripts are induced when terminal differentiation is induced in 
mouse epidermis (Riggs et al. 2005), and expression has been shown to affect cellular motility in 
vitro (Arai et al. 2008), we hypothesized that the abundance of NMES1 in the testis might reflect 
a role for the gene during spermatogenesis.  If NMES1 is important during any stage of testis 
development or spermatogenesis, expression of this gene could also affect male fertility.
1
 
To date, the functions of proteins encoded by many genes involved in both testis 
development and spermatogenesis remain unknown or poorly characterized.  Better 
understanding of genetic regulation of spermatogenesis is important because stallion fertility can 
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have significant economic consequences for the horse breeding industry.  The economic impact 
due to stallion sub-fertility can be manifested in lost stud fees, increase in veterinary expenses, 
increased management costs, and ultimately a loss of genetic contribution from prized stud 
horses (Oristaglio Turner 2007).  Stallion fertility traits are rarely selected for within the industry 
and thus have not been under strong selective pressure (Loomis 2006).  This practice has led to 
an industry that economically benefits from stallion fertility, but has not selected towards 
increasing the success of this trait. 
Because NMES1 is abundantly expressed in the testis, but its function and role in 
spermatogenesis, if any, remain unknown, the work described in this thesis focused on genomic 
characterization of the NMES1 gene.  The objectives of this project were to characterize the 
NMES1 gene in the equine genome and to begin analyses to determine the function of the 
NMES1 protein in stallion testis.  If NMES1 contributes to stallion fertility, these data could lend 
new knowledge toward understanding of autosomal gene contribution in male fertility.   
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2. LITERATURE REVIEW 
2.1 INDUSTRY IMPORTANCE 
 
 The equine industry contributes approximately $39 billion dollars annually to the U.S. 
economy according to a 2005 study conducted by Deloitte Consulting, LLP for the American 
Horse Council Foundation.  The industry is set-up in such a way that one stallion services many 
mares in the breeding pool.    This structure allows for a large amount of potential money loss 
due to stallion infertility.  Resources are lost when a stallion with a performance record is set up 
at stud and little to no progeny are produced.  Breeding managers, and stallion owners, as well as 
mare owners, lose profits from costs associated with repeated breedings that produce no 
offspring.  Throughout the domestic horse’s history, many traits have been selectively bred for 
by humans; however, fertility traits have never been included on that list.      
 
 
2.2 TESTIS DEVELOPMENT 
 
 The mammalian system for sex determination is unique in that mammals have a bi-
potential gonadal system (Wilhelm et al. 2007).  The bi-potential gonad is a mixed population of 
cells that contains both somatic and germ cell tissues (Kim et al. 2006).  During early 
development, the presence of appropriate gene products tip the scale in one direction or another 
and starts the embryo on its path toward becoming male or female (Wilhelm et al. 2007).  Before 
this fate has been determined, the urogenital ridge development is the same for males or females 
(Sim et al. 2008).  In mammals, the presence or absence of the Y chromosome with an intact 
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SRY gene is the male determinant (Sekido et al. 2004).    In the presence of SRY expression the 
urogenital ridge differentiates into a testis instead of an ovary.  Expression of male hormones 
from the differentiated testis drives development of all other secondary sexual traits in males 
(Wilhelm et al. 2007). 
The sex determining factor gene on the Y chromosome, SRY, was identified in 1990 
(Sinclair et al. 1990).  Sry is a member of the Sox family of transcription factors.  This family of 
transcription factors contain a high mobility DNA binding domain, or HMG (Wilhelm et al. 
2007)..  Unlike other members of the Sox family, SRY has no classic domains for transcriptional 
activation and repression (Bernard et al. 2008).  SRY is expressed specifically in the tissues that 
give rise to immature Sertoli cells, which are present in the developing testis (Wilhelm et al. 
2007).  In mice, expression of Sry starts around 10.5 days post coitum (dpc) and is characterized 
as being a wave of expression, starting from the center of the urogenital ridge and spreading 
outward towards the poles of the ridge (Wilhelm et al. 2007).  This happens by 11.5 dpc.  After 
expression has reached the poles, Sry is down-regulated starting in the center of the ridge and 
spreading out towards the poles again.  Sry expression ceases at 12.5 dpc (Kidokoro et al. 2005).  
Soon after the expression of Sry, expression of Sox9 is up-regulated (Sekido et al. 2004).  
Because expression of Sry is no longer detectable by 12.5 dpc, Sry expression is not responsible 
for the continuation of male gonadal development, but rather only acts as a switch to start the 
process (Sim et al. 2008).      
 Sertoli cells derive from coelomic epithelium, part of the urogenital ridge that can give 
rise to interstitial cell types.  Experiments were conducted to determine which cell types 
expressed SRY in embryonic mice.  To answer this question Sekido and colleagues (Sekido et al. 
2004) constructed two transgenes fused to the SRY promoter.  They developed the first transgene 
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using human placental alkaline phosphatase (hPLAP) inserted to replace the 5’ end of the coding 
sequence to give a stable reporter, and developed the second transgene using a Myc-epitope tag 
inserted directly in front of the stop codon of SRY.  They were then able to make transgenic 
mouse embryos and look at expression of the SRY transgenes by using an anti-Myc antibody to 
use for immunostaining during the developmental process and by looking at hPLAP enzyme 
activity.  The results from the experiment showed that only the Sertoli precursor cells showed 
SRY expression.  Only those cells which had SRY expression showed expression of Sox9.  The 
results from this study concluded that only precursors of Sertoli cells express SRY and Sox9 and 
continue on to become functional Sertoli cells without the recruitment of other cell types (Sekido 
et al. 2004).   
Sox9 is a proposed target gene of SRY.  Sox9 is expressed at low levels in the urogenital 
ridge in both males and females at 10.5 dpc.  At 11.5 dpc however, Sox9 expression is strongly 
up-regulated in males and down-regulated in females (Sekido et al. 2004).  It has been shown 
that Sox9 expression is up-regulated in a similar wave pattern as that of SRY, starting in the 
center of the urogenital ridge and moving outward.  This information suggests that Sox9 is the 
first target of SRY (Bernard et al. 2008).  It has been shown that if SRY is absent, supplementing 
with Sox9 expression will induce testis formation.  This evidence also points toward Sox9 being a 
conserved target of SRY  (Qin & Bishop 2005).  Sox9 affects the regulation of many genes, 
including anti-Mullerian hormone (Amh) and Vanin-1 (Vnn1) (Wilhelm et al. 2007).   
Chaboissier et al. (2004) were interested in studying the in vivo effects of Sox9 
expression.  They developed a Sox9 conditional knock-out transgenic mouse line.  Urogenital 
ridges were dissected from heterozygous and homozygous conditional knock-out mouse embryos 
and real-time quantitative PCR (qRT-PCR) was used to analyze expression levels of Sox9.  In 
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heterozygous male knock-outs, expression of Sox9 was reduced to levels similar to that of 
females.  The male embryos developed irregularly-formed sex cords.  Expression of Amh 
behaved in linear fashion to the expression of Sox9 suggesting again that Amh is a target for 
Sox9.  Data for homozygous conditional knock-outs showed almost complete sex reversal from 
male to female.  These male embryos lacked sex cord development and were histologically 
similar to the females.  In fact, expression of Bmp2 and follistatin was observed, both of which 
are markers for female sex determination (Chaboissier et al. 2004).   
To date, the only known morphological event associated with the expression of SRY is an 
increase in cell proliferation.  Throughout embryo development, a recurring theme is the 
proliferation and movement of progenitor cells.  This is also an important event in testis 
development.  Experiments designed to study cell proliferation in response to SRY expression 
were conducted by Schmahl and Capel (2003).  It had been shown previously in other organ 
systems that if proliferation is blocked, differentiation is halted.  In order to determine whether 
proliferation played any role in testis development, these researchers used cell proliferation 
inhibitors both in vivo and in culture.  Pregnant female mice were injected with proliferation 
inhibitors at specific time points and then embryos were harvested for inspection and dissection.  
When proliferation inhibitors were injected between day 10 and 11 dpc, the male embryos failed 
to form testis cords.  The gonads of both male and female embryos were smaller in size after 
injection when compared to controls (Schmahl & Capel 2003).   
In the Schmahl and Capel study (2003), the relationship between cell proliferation and 
male-specific gene expression was examined.  Under normal developmental conditions, Amh and 
Sox9 expression can be detected at 12.5 dpc in Sertoli cells located within testis cords in male 
XY embryos.  When embryos received injections in the critical window between day 10 and 11 
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dpc, expression of Sox9 and Amh was abnormal in regards to localization, reduced expression, or 
loss of expression.  These results demonstrated that Sertoli cells and testis cord formation are 
affected by inhibition of cell proliferation and that Sox9 and Amh expression levels and patterns 
are also affected (Schmahl & Capel 2003).  SRY has been shown to affect cell proliferation and it 
is proposed that this is one of the mechanisms by which SRY initiates male gonadal development 
(Kidokoro et al. 2005).   
 
 
2.3 SPERMATOGENESIS 
 
In stallions, a distinct pattern of maturation occurs within the testis.  Lighter colored 
seminiferous tubules undergo spermatogenesis and are present in the testis core, while dark 
immature tissue surrounds the periphery.  The testis matures slowly from the center outward as 
the stallion completes puberty and seminiferous tubules develop and start spermatogenesis 
(Clemmons et al. 1995).   
As spermatogenesis begins during this process of inner light tissue spreading outwards 
during testis maturation, gonocytes are converted to spermatogonia.  Spermatogenesis begins at 
this stage and occurs with a physiological wave of apoptosis (Rodriguez et al. 1997).  As this 
first division of germ cells occurs, a surge of apoptosis spreads through the testis which aids in 
the development of seminiferous tubules by removing germ cells from the epithelium of the 
tubule.  This process is necessary for maturation of the seminiferous tubules.  In a study that 
measured apoptosis within the seminiferous tubules, a classification system was developed to 
rank the tubules from L1 to L7 according to the level of testis maturation (Staub et al. 2002).  
The classification system ranked the samples based on the lumen score of the seminiferous 
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tubules.  A score of L1 indicated that the lumen was completely closed and developmentally 
immature.  Scores of L2-4 indicated that the lumens had increasing numbers of vacuoles within 
the tubules.  A tubule with a score of L5 and L6 was given to tubules with large lumen and a 
complete lumen that was lacking complete generations of germ cells respectively.  The L7 score 
was reserved for tubules with complete lumen formation that contained full germ cell 
populations.  These experiments demonstrated a peak in apoptosis during the L6 type tubules 
that showed mature development of the tubule epithelium.  The L6 tubules contained fewer germ 
cells than the next class of tubules (L7) that are marked by complete tubule development and 
spermatogenesis (Staub et al. 2002).  This ordered and distinct pattern of tissue maturation and 
apoptotic wave leads to the final development of mature and complete seminiferous tubules 
where spermatogenesis occurs in the mature testis.   
 
 
2.4 NMES1 
 
NMES1 was first characterized by Zhou et al. (2002) during an investigation of gene 
expression in human esophageal squamous cell carcinoma.  Experimental data from RT-PCR, 
northern blot, and immunohistochemistry showed a decreased expression of NMES1 in 
esophageal carcinomas compared to the surrounding “normal” mucosal tissue.  Some carcinomas 
completely lacked expression, and neither RNA nor protein could be detected (Zhou et al. 2002).  
A subsequent study (Riggs et al. 2005) identified differentially expressed genes in the epidermis 
of strains of mice either susceptible (DBA/2J) or resistant (C57BL/6J) to tumor formation in a 
two-stage carcinogenesis experiment.  The phorbol ester, 12-O-tetradecanoyl-13-phorbol acetate 
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(TPA) can be used to promote tumor growth in mice following carcinogen exposure and are also 
known to induce terminal differentiation in mouse epidermis (DiGiovanni 1992). The two strains 
of mice were treated with TPA or vehicle (acetone), and RNA was extracted from dorsal 
epidermis tissue for microarray analysis.  In the previous study (DiGiovanni 1992), tumor 
promotion sensitive mice (DBA/2J) demonstrated a marked increase in epidermal inflammation.  
The microarray data indicated that the promotion-resistant C57BL/6J mice strongly induced 
epidermal NMES1 expression in response to TPA treatment.  Expression of Nmes1 in C57BL/6J 
epidermis was about 10-fold greater than expression in promotion-sensitive DBA/2J mice (Riggs 
et al. 2005).   
 Arai and colleagues (2008) investigated the methylation status of the promoter region of 
genes shown to exhibit higher expression after treatment with 5-aza-2’-deoxycytidine (DAC) in 
human esophageal squamous cell carcinoma (ESCC) cell lines.  DAC is known to reactivate 
genes that have been silenced through methylation (Cameron et al. 1999).  From microarray 
experiments conducted to identify genes induced by the DAC treatment.  NMES1 was identified 
as a candidate gene (Arai et al. 2008).  Additionally, Boyden chamber assay experiments showed 
that when NMES1 was over-expressed in two transfected ESCC lines, motility of the cells was 
significantly decreased compared to the parental cell lines (Arai et al. 2008).  A similar 
microarray analysis was done on invasive cervical cancer cell lines by another lab and NMES1 
was found to be hypermethylated in cervical cancer cells (Sova et al. 2006).  Based on these 
experiments, methylation and subsequent loss of NMES1 gene expression may contribute to 
tumor development.   
 Most recently, Liu et al. (2009) demonstrated that NMES1 encodes the microRNA, miR-
147b, in its 3’-untranslated region (3’UTR), and showed that increased miR-147 expression 
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dampens inflammatory response, particularly in macrophages.  Interestingly, decreased miR-147 
was implicated as a possible gene expression signature in coronary artery disease patients 
(Hoekstra et al.).  The function of NMES1 and its associated microRNA remain unclear, and it is 
not known if the NMES1 gene can be expressed independently of the microRNA.   
 It has been noted that full lenth, capped, polyadenylated mRNAs can act as a primary 
miRNA transcript.  These mRNAs are able to function normally as well, and can therefore be 
translated into proteins.  It is also possible for the mRNAs to only function as pri-miRNAs (Cai 
et al. 2004).  miRNAs have also been shown to act on genes involved in pathways that affect 
testis development and spermatogenesis.  Expression of Tnp2,which  is testis specific, has been 
shown to be reduced by miR-122a (Yu et al. 2005).  miR-34c is a miRNA that is highly 
expressed in testicular germ cells and present in pachytene spermatocytes and round spermatids 
(Bouhallier et al. 2010).  The miR-34 family of microRNAs have been shown to be regulated by 
p53 (He et al. 2007).  miR-34c acts to reduce cell proliferation by down-regulating genes 
associated with cell proliferation within the testis and this is postulated to play a role in the 
spermatogenesis process (Bouhallier et al. 2010).      
Based on unpublished data and previous studies (Riggs et al. 2005; Arai et al. 2008), we 
hypothesized that NMES1 may play a role in cellular differentiation and growth.  Because of the 
abundant expression in the testis, NMES1 may play in integral role in the differentiation of 
spermatogonia within the seminiferous tubules.  If the function of NMES1 is important during 
spermatogenesis, its expression may affect stallion fertility. 
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3. MATERIALS AND METHODS 
3.1 BAC LIBRARY SCREENING 
 
A PCR assay designed to amplify the last exon of the equine NMES1 gene was used to 
screen the CHORI-241 equine BAC library for a clone containing the NMES1 gene.  Super pools 
of CHORI-241 clones were first screened, and then positive single pools were identified.  The 
single pools were then screened to determine column and row position of the positive clones 
within the BAC library.   
The PCR assay consisted of 17.2 µl H2O, 2.5 µl 10x PCR Buffer, 1.5 µl 25mM MgCl2, 
0.75 µl each forward (5’-sequence) and 0.75 µl reverse (5’-sequence) primers (IDT, location), 
1.0 µl 2.5 mM dNTP mix (vendor, loc), 0.3 µl Amplitaq® (Applied Biosystems, Carlsbad, CA), 
and 1.0 µl template DNA (n ng) from the BAC library pools. The components were denatured at 
94°C for 3 min, followed by 30 cycles of 94°C for 15 seconds, 60°C for 45 seconds, and a final 
extension step at 60°C for 6 min.  
The PCR products were combined with 5µl 5x loading buffer (vendor) containing 
bromophenol blue dye and SYBR® green I (Invitrogen, Carlsbad, CA). For product 
visualization, 15 µl were electrophoresed through a 2% agarose gel in 1X tris-borate-edta buffer 
(TBE) at 65V for 2.5h.  Bands in the gel were visualized under ultraviolet light.  After screening 
the library, we identified a positive clone, CH241-11J8, and proceeded to generate BAC DNA. 
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3.2 DNA EXTRACTION 
 
A large construct kit (Qiagen, Valencia, CA) was used for extraction of BAC DNA from 
the selected clone.  Following manufacturer’s instructions, 500 ml Luria broth (LB) cultures 
were inoculated with the selected BAC clone and DNA was extracted.  BAC DNA quantity was 
measured on a NanoDrop ND-1000 spectrophotometer.  The PCR assay used to screen the 
library was then performed on the extracted DNA to confirm the presence of our gene of interest, 
following the PCR assay protocol listed above in Section 3.1  
 
 
3.3 SEQUENCING 
 
Automated sequencing was performed with an ABI 3730xl sequencer.  Reaction 
components included Big Dye® v.1.1 components (Applied Biosystems, Carlsbad, CA).  
Purified BAC DNA was used as the template material.    Each  7µl reaction included 1 µg  
template DNA, 1.5 ul 5X buffer,  0.5 ul primer (10 uM).   The reactions were denatured at 98°C 
for 2 min, then immediately quenched on ice for 2 min.  1 µl Big Dye v. 1.1 was added to each 
reaction and the sequences were loaded on an ABI 2720.  The reactions were denatured at 95°C 
for 5 min then amplified for 99 cycles of: 96°C for 30 sec, 50°C for 10 sec, and 60°C for 4 min. 
The sequences were purified through Dye-Ex spin columns (Qiagen, Valencia, CA) and 
the samples were dehydrated by vacuum centrifugation before being resuspended in 10 µl Hi-
Di™ formamide (Applied Biosystems, Carlsbad, CA).  The samples were transferred to a 96-
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well plate, denatured at 98°C for 2 min and then quenched on ice for 2 min before being loaded 
onto an ABI 3730xl.  The sequence data was analyzed with Sequencher® 4.8 software.         
 
 
3.4 PRIMER DESIGN 
 
 Oligo 6® was used for primer design.  The initial sequencing reaction was conducted 
with the primers assay already designed for screening the CH241 library while BAC DNA 
sequence derived from the initial sequencing reaction was used for further primer design to 
enable “primer walking” in the 5’ and 3’ directions.  Primers were designed to amplify only the 
equine NMES1 gene.  The primers designed and used for the BAC sequencing experiment are 
listed in the Table 1. 
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Table 1 Complete list of primers used for sequencing CH241-11J8.  All primers are 
written in 5’ to 3’ orientation.   
GAATCCAAATGTCCACCAA CTAAAAATGTAGCAGAAGCA 
GTCGGGTACTGGGAACAA GGAAGCCCATTGAAGAGT 
CCTCCTTGACTGTTCTTGAA AGTGTTCTTGCCCTGGTT 
CATCCAGCGTTCTCCAA AACCAGGGCAAGAACACT 
TCGGACTCTGGATAAGGA TTACTATGGGCGAGGCACT 
ACGCTTGTGGCAGTGTTA AGTGCCTCGCCCATAGTAA 
ACGCCACCAAAGGAATAAGCTA CTGGGGTGATAGAGAACTTGT 
AGTGCCTCGCCCATAGTAA GAGCACCATTTGTCAGCCTT 
CATAAGGGAAAGGTAGAGA  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
3.5 RLM-RACE 
 
 Total testis RNA from three different mature stallions was kindly provided by Dr. Nancy 
Ing, and was processed with the RNeasy cleanup kit (Qiagen, Valencia, CA) and DNAse treated 
(DNA-free™; Ambion, Austin, TX).  Quality and integrity of RNA samples was assessed by 
capillary electrophoresis on an Agilent 2100 Bioanalyzer.  RACE reactions were prepared with 
the First Choice® RLM-RACE kit (Ambion, Austin, TX).  1 µg starting RNA was used for each 
of the three samples.  The kit protocol was followed precisely, adding 2 µl of glycogen during 
the RNA precipitation step.  An oligo d(t)20 primer was used for reverse transcription (RT).   
Four µl RT product was amplified by PCR.  A set of primers was designed with Oligo 6® 
software.  The forward primer was designed from the RACE adapter sequence.  The reverse 
primer was gene-specific and based on NMES1 sequence obtained from sequencing the BAC 
clone (5’-CGAAAAAGAAATCCAGAACCT-3’).  The reaction was run on an ABI 2720 at 
94°C for 3 min, 35 cycles of 94°C for 30 sec, 58°C for 1 min, 72°C for one min, and then 72°C 
for 7 min. 
The PCR products were evaluated by electrophoresis. 5 µl reaction plus 2 µl 5x loading 
buffer containing bromphenol blue and SYBR® green I was electrophoresed through a 2% TBE 
gel.  The gel was run at 30 mA for 2.5 hrs.  Bands were visualized under UV light. 
Product was observed for only one of the three samples.  Two products were amplified in 
the PCR reaction.  For sequencing of each product, the bands were stabbed with a pipette tip and 
added to two new PCR reactions with the same components as above.  The assay was repeated 
under the same parameters as above. After electrophoresis, each PCR reaction amplified a single 
discreet product.   
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The two PCR products were then ligated into the pCR®II vector (Invitrogen, Carlsbad, 
CA).  1 µl PCR reaction was combined with the vector in a ligation reaction according to 
manufacturer’s recommendations. The ligation reaction was incubated at 14°C overnight and a 
portion of the reaction mix was transfected into chemically competent DH5α cells. 75 µl 
transformed cells were plated on agar plates containing 50 µg/ml ampicillin, 40 µl 100mM 
IPTG, and 40 mg/ml X-Gal.  Plates were incubated at 37°C overnight.  White colonies were 
selected and grown in 5 ml LB broth cultures with ampicillin (50 µg/ml) overnight.   
To verify correct insertion of the PCR product into the vector, a PCR assay using 
standard M13 primers was performed on the broth cultures.  5 µl of culture was added to 100 µl 
of water and denatured for 10 min at 95°C.  5 µl of this sample was added to a PCR reaction 
containing and run at the on an ABI 2720 as follows: 95°C for 5 min, 35 cycles of 95°C for 30 
sec, 50°C for 30 sec, 72°C for 30 sec, and then 72°C for 7 min. 
 Once insertion of correct-sized product was verified, the PCR reaction was cleaned using 
the Psi-Clone kit (Princeton Separations, Freehold, NJ).  The products were then quantified by 
NanoDrop spectrophotometry. 
 In order to obtain 3’UTR sequence of the NMES1 gene, 1 µg of starting RNA from the 
three stallion testis RNA samples prepared for the 5’RLM-RACE experiment were used.  The 3’ 
RACE protocol was followed, using the same First Choice® RLM-RACE kit (Ambion, Austin, 
TX).  A gene specific forward primer (5’-GATCCTAGTGTACCTACAAA-3’) was designed 
using the BAC sequence, while a reverse primer was designed from the 3’ RACE adapter 
sequence.   
 The PCR products were analyzed by running 5 µl of the reaction plus 2 µl of 5x loading 
buffer with Bromphenol Blue and SYBR® green on a 2% TBE gel.  The gel was run at 30 
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mAmps for 2.5 hours..  Bands were visualized over a UV light box.  Discreet products were 
obtained so the reactions were cleaned using the Psi-Clone (Applied Biosystems, Carlsbad, CA) .   
 
 
3.6 5’ AND 3’ UTR SEQUENCING 
 
The sequencing reactions were carried out as described above except that, after addition 
of Big Dye®, PCR was conducted for 25 cycles of: 96°C for 10 seconds, 50°C for 5 seconds, 
and 60°C for 4 min.  The sequence data was then analyzed using Sequencher® 4.9 software to 
build a contig and determine a consensus sequence.         
 
3.7 LABELING OF BAC DNA WITH DIGOXIGENIN 
 
To determine the chromosomal location of the equine NMES1 gene, the CH241-11J8 
clone DNA was labeled with digoxigenin by nick translation.  1 µg BAC DNA was added to 4 µl 
of dig nick translation mix and ddH2O to a final volume of 20 µl.  The reaction was incubated at 
15°C for 90 min.  After incubation, 25 µl double distilled H2O was added to the reaction and the 
sample was purified on a spin-50 minicolumn (USA Scientific, Ocala, FL) following 
manufacturer’s protocol.  5 µl of the eluate was combined with 2 µl of loading buffer and 
electrophoresed through a 1% agarose gel for 30 min at 100 V to assess progress of nick 
translation reaction.  The sample was mixed with 15 µl of 1µg/µl unlabeled equine genomic 
DNA and dehydrated.  The probe was resuspended in 6 µl of H2O and 14 µl of hybridization 
master mix (50% formamide, 10% dextran sulfate, and 2X SSC).  The probe was stored at -20°C 
until used. 
 18 
 
3.8 FLUORESCENCE IN SITU HYBRIDIZATION WITH LABELED BAC 
 
Equine metaphase chromosome slides were obtained from Dr. Terje Raudsepp.  The 
slides were examined with phase contrast microscopy and areas approximately 4x4mm
2
 
containing good quality metaphase spreads were marked with a diamond pencil.  500 µl RNase 
was added to the slides.  A 24x60 mm cover slip was applied and the slides were incubated at 
37° for 1 hour.  The cover slip was removed and the slides were washed for 2 min in 2X SSC 
and then dried in an ascending ethanol series for 2 min each wash.  The slides were denatured in 
70% formamide with 2X SSC at 70°C for 10 min.  The slides were then washed in ice-cold 70% 
EtOH and dehydrated in an ascending ethanol series and allowed to air dry.   
The labeled probe from the above section was prepared for hybridization.   2.5 µl of 
probe was added to a microcentrifuge tube and was denatured at 95° for 11 min.  The probe was 
then preannealed at 37°C for 20 min.  The probe was then pipetted onto the marked areas on the 
slides and a cover slip was cut to fit the area.  The cover slip was added and sealed with rubber 
cement.  The slides were incubated at 37°C overnight in a humid chamber. 
Following hybridization, the rubber cement was removed and slides were washed in 50 
ml 2X SSC to remove the cover slips.  The slides were washed in 3 changes of 50 ml 50% 
formamide with 2X SSC (5 min at 40°C); 3 changes of 50 ml 4X SSC with 0.05% Tween-20 (2 
min with shaking); 50 ml 4X SSC for 2 min with shaking. 
For signal detection, an antibody layering protocol was used.  The antibodies were 
diluted in 200 µl per slide of 1X blocking solution.  Layer 1 consisted of 0.8 µl anti-dig antibody 
in 200 µl 1X blocking solution and added to the slide.  A cover slip was applied and the slide 
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was incubated at for 30 min at 37°.  The slides were washed in 3 changes of 50 ml 4X SSC with 
0.05% Tween-20 (2 min with shaking), followed by 50 ml 4X SSC for 2 min with shaking.  
Layer 2 consisted of 0.4 µl of anti-mouse Ig-dig antibody added to 200 µl 1X blocking solution 
and added to the slide.  A cover slip was applied and the slide was incubated at for 30 min at 37°.  
The slides were washed in 3 changes of 50 ml 4X SSC with 0.05% Tween-20 (2 min with 
shaking), followed by 50 ml 4X SSC for 2 min with shaking.  Layer 3 consisted of 1 µl of 
antidig-rhodamine stock solution added to 200 µl 1X blocking solution and added to the slide.  A 
cover slip was applied and the slide was incubated at for 30 min at 37°C.  The slides were 
washed in 3 changes of 50 ml 4X SSC with 0.05% Tween-20 (2 min with shaking), followed by 
50 ml 4X SSC for 2 min with shaking.  The DAPI-antifade was applied to the slide and cover 
slips were mounted. Slides were stored at -20°C in the dark for approximately 20 min before 
being examined for signal.  The slides were examined using fluorescence microscopy and 
analyzed using software.. 
  
 
3.9 TESTIS PROCESSING AND HISTOLOGY 
 
Fresh testis tissue was collected from a 2.5 year old stallion.  The tunica was removed 
and the testis was dissected into approximately 0.5 cm wide sections taken from the mature 
tissue containing seminiferous tubules.  Tissue from the core of the testis that mostly contains 
collecting ducts was avoided.   
The tissues were placed in individual 50 ml conical tubes and were incubated in 45 ml 
4% paraformaldehyde rotating at room temperature for 24 hours.  The paraformaldehyde was 
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decanted and the tissues were washed and incubated in 45 ml 50% ethanol for 12 hours.  The 
ethanol was changed and the tissues were incubated again for 12 hours.  The 50 % ethanol was 
then decanted and replaced with 45 ml 70% ethanol.   The tissues were incubated for 12 hours 
and the tissues were then placed in labeled cassettes and fresh 70% ethanol.  Tissues were 
embedded in Paraplast® (Structure Probe, Inc., West Chester, PA) and sections cut at thickness 
of 5 µm for slides at the Veterinary Integrative Biosciences Histology Laboratory at Texas A&M 
University.  The sections were affixed to plus coated slides and stored at 4°C.  At least one slide 
per block was stained with hematoxylin and eosin to help determine tissue morphology. 
 
 
3.10 PROBE DESIGN 
 
An equine NMES1 specific probe was designed to use for in situ hybridization 
experiments.  The genomic NMES1 sequence determined from the BAC clone was aligned with 
mouse and human sequences to determine the probable coding sequence.  Primers were then 
designed based on this sequence to make a 250 nt long product that was within the start and stop 
sites and complimentary to the NMES1 mRNA transcript present in the testis.  The primers were 
designed using Oligo 6 and specificity to the equine genome assembly was verified by BLAST.   
cDNA was synthesized from total RNA that was extracted from the testis tissue that was 
collected for histologic analysis.  This RNA processed through RNeasy clean-up columns 
(Qiagen, Valencia, CA) and was DNase treated with DNA-free™ (Ambion, Austin, TX).  The 
RNA was quantified by NanoDrop spectrophotometry.  Two µg of total RNA was used in the RT 
reaction and the protocol was followed as in Section 3.17. 
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The PCR assay was conducted using the above designed primers and was as follows: 
17.2 µl H2O, 2.5 µl 10x PCR Buffer, 1.5 µl 25mM MgCl2, 0.75 µl gene specific forward primer, 
0.75 µl gene specific reverse primer, 1.0 µl 2.5 mM dNTP mix, 0.3 µl Amplitaq®, and 1.0 µl 
template DNA from the BAC library pools.  PCR was conducted under the following 
parameters: 94°C for 3 min followed by 30 cycles of 94°C for 15 sec, 60°C for 45 sec. The PCR 
products were electrophoresed through a 2% TBE gel for band visualization.  2µl 5x loading 
buffer with dye and Sybr® green were added to each 5 µl of the PCR reaction, then loaded onto 
the gel and run at 65 V for 2.5 hrs.  The gel was then visualized over a UV light box.  The PCR 
product was purified with the Psi-Clone kit and reagents to remove inhibitory reaction 
components.   
 This clean PCR product was ligated into a PCRII plasmid vector using the TA Cloning® 
kit with Dual Promoter from Invitrogen (Carlsbad, CA).  3µl of the product was used in the 
ligation reaction following the kit protocol.  The reaction incubated overnight at 14°C.  The 
plasmid was then transfected into Top10F’ chemically competent cells, according to the 
manufacturer’s recommendations.  20 µl of the transformed cells were plated on agar plates with 
50 µg/ml ampicillin, 40 µl 100mM IPTG, and 40 mg/ml X-Gal.  The plates were incubated 
overnight at 37°C.  White colonies were selected and grown in 5 ml LB broth cultures with 50 
µg/ml ampicillin.  The cultures were incubated at 37°C in a shaking water bath overnight. 
 To further verify PCR product insertion, a PCR assay was conducted using standard M13 
primers.  The 50 µl assay contained the following: 31.4 µl H2O, 5 µl 10x PCR Buffer, 5 µl 
15mM MgCl2, 1 µl 10mM M13 forward primer, 1 µl 10mM M13 reverse primer, 0.6 µl 5 mM 
dNTP mix, 1 µl Taq polymerase, and 5 µl template broth culture.  PCR conditions consisted of 
94°C for 3 min, followed by 30 cycles of 94°C for 15s, 60°C for 45s. The PCR products were 
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visualized in a 2% agarose gel as described above.  After successful ligation was confirmed, 200 
µl of the 5ml broth culture was added to a 100 ml LB broth culture with ampicillin (50 µg/ml) 
and were incubated at 37°C overnight in a shaking water bath.  Plasmid DNA was extracted from 
the culture with a large insert maxi-prep kit (Qiagen, Valencia, CA) according to manufacturer’s 
instructions.  The plasmid DNA was then quantified by spectrophotometry. 
 The DNA was sequenced to determine the orientation of the PCR product insertion.  
Products were sequenced as previously described except that M13 forward or reverse primers 
were used. 
 The plasmid was then digested with two separate restriction enzymes in order to 
synthesize a sense and antisense probe.  SpeI and EcoRV were used to digest the plasmid in two 
separate reactions.  10 µg of plasmid DNA in 170 µl water was added to 20 µl 10X restriction 
enzyme buffer and 10 µl of the appropriate restriction enzyme.   The reaction was incubated at 
37°C overnight.  A sample of the digested plasmid was run on a 1% TBE gel for digest 
verification.  2µl 5x loading buffer with dye and SYBR® green were added to each 5 µl the PCR 
reaction, and then loaded onto the gel and electrophoresed at 50 V for 1 hr.  The gel was then 
visualized over a UV light box. 
 The digested DNA was extracted from the digest reaction with an equal volume of 
phenol:chloroform:isoamyl alcohol, followed by chloroform extraction.  The DNA was then 
precipitated with 3 volumes of 100% ethanol and 1/10
th
 volume sodium acetate.  The pelleted 
DNA was resuspended in 40 µl water and quantified. 
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3.11 PROBE LABELING WITH DIGOXIGENIN 
 
 The digested plasmid samples were labeled with digoxigenin by using the Dig RNA 
Labeling kit (SP6/T7) from Roche (Indianapolis, IN).  The protocol given with the kit was used.  
1 µg of the digested plasmid DNA from the above section was used.  The sample digested with 
EcoRV was used with the SP6 promoter, while the sample digested with Spe1 was used with the 
T7 promoter.  After the Dig incorporation reaction, the reactions were cleaned using Centri-Sep 
Spin Columns (Princeton Separations, Freehold, NJ).  The transcripts were checked on a 
formaldehyde gel (68 ml DEPC treated ddH20, 8 ml 10X MOPS, 0.8 g Agarose, and 4 ml 
formaldehyde).  The probe was prepared for loading (2.0 µl labeled probe, 0.5 µl formamide, 2.7 
µl formaldehyde, 1.5 µl 10X MOPS, 1.6 µl Loading Buffer, 0.2 µl 10 ng/µl Ethidium Bromide, 
and 1.0 µl DEPC treated ddH2O) then incubated at 70°C for 10 min and quenched on ice.  The 
sample loaded on the gel and run at 100 Volts for 1 hr.  The gel was then visualized on a UV 
light box to verify labeled transcripts.   
 To determine labeling efficiency, samples were tested on a dot blot.  The dot blot was 
conducted using reagents from the DIG Nucleic acid Detection kit (Roche, Indianapolis, IN).  
The protocol from the kit was followed.  The dot blot results indicated the efficiency and the 
probes were diluted to 10 ng/µl and stored at -80°.  
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3.12 IN SITU HYBRIDIZATION WITH POLY d(T) PROBE 
 
To determine the RNA quality of the tissue, an in situ experiment was conducted using a 
poly d(T) probe that was obtained from Roche (Indianapolis, IN).   Slides were incubated at 
55°C for 10-15 min to melt the Paraplast.  The slides were washed in 2 changes 50 ml Citrisolv 
(3 min), 2 changes 50 ml 100% EtOH (3 min), 50 ml 95% EtOH (3 min), and 50 ml DEPC-
ddH2O (3 min).  The slides were incubated with 100 µl 5 µg/ml Proteinase K in 0.05M Tris/HCl 
pH 7.6 at 37°C for 30 min.  The slides were washed in 2 changes 50 ml DEPC-ddH2O (3 min), 
50 ml 95% EtOH (3 min), and 50 ml 100% EtOH (3 min).  The slides were allowed to air dry 
and 20 µl prepared probe hybridization solution was added to the slide.  Cover slips were added 
and the slides were incubated in a humid chamber for 15 min at 65°C then at 37°C for 2 hrs.    
Slides were washed in 3 changes 50 ml TBS with 0.1% Triton X-100 (3 min) and then 
incubated with 100 µl normal rabbit serum diluted 1:5 in TBS containing 3% BSA, 0.1% Triton 
X-100 for 10 min. The slides were incubated with 100 µl provided Antibody at a 1:200 dilution 
per slide for 30 min.  The slides were washed for 2 changes in 50 ml TBS (3 min) and 50 ml 
alkaline phosphatase substrate buffer pH 9.0 (5 min).  The slides were incubated with 100 µl 
color solution per slide, and cover slips were placed and sealed with rubber cement.  The slides 
were incubated at room temperature overnight in the dark.  The slides were washed with tap 
water (5 min) then mounted using Crystal Mount.    
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3.13 IN SITU HYBRIDIZATION WITH DIGOXIGENIN-LABELED PROBES 
 
 Once it was determined that the prepared tissue slides had sufficient quality RNA, the in 
situ experiment was repeated using the labeled probe that we synthesized.  The slides were 
incubated at 55°C for 10-15 min to melt the Paraplast® (Structure Probe, Inc., West Chester, 
PA).  The slides were washed in 3 changes 50 ml CitriSolv (5 min), 2 changes 50 ml of 100% 
EtOH (2.5 min), 2 changes 50 ml of 95% EtOH (2.5 min), 2 changes 50 ml 70% EtOH (2.5 min), 
2 changes 50 ml of DEPC-ddH2O (2 min), 2 changes 50 ml of 1X PBS (5 min), 50 ml 1X PBS 
with 0.3%Triton for 15 min, 2 changes 50 ml 1X PBS (5 min), 50 ml 5 µg/ml Proteinase K in 
10mM Tris, 1mM EDTA, pH 8.0 for 10 min, 50 ml 1X PBS with 4% paraformaldehyde for 5 
min at 4°C, 2 changes 50 ml 1X PBS (5 min), 2 changes 50 ml 1X PBS with 100mM glycine (3 
min), 2 changes 50 ml 1X PBS (5 min), 2 changes 50 ml 0.1 M TEA with 125 µl of acetic 
anhydride (5 min), 2 changes 50 ml 1X PBS (5 min), 50 ml Pre-Hybe solution (4XSSC and 50% 
Formamide) for 1 hr at 37°C. 
The probe was then prepared for hybridization to the section.  For each slide, 2 µl dig-
labeled probe (10 ng/µl) was added to 52 µl of hybridization buffer (40% de-ionized formamide, 
10 % dextran sulfate, 1X Denhardt’s solution, 4X SSC, 10 mM DTT, and 1 mg/ml yeast tRNA) 
and 6 µl denatured and sheared salmon sperm DNA (1 mg/ml).  This probe mixture was 
denatured at 70°C for 10 min and then quenched on ice.  60 µl of the prepared probe was 
pipetted to the center of each slide, cover slipped, and sealed with rubber cement.  The slides 
were incubated at 50°C in a humid chamber (chamber prepared with Whatman paper soaked in a 
solution 4X SSC and 50% Formamide) overnight. 
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Rubber cement was removed and the slides were washed in 50 ml 2X SSC for 5 min to 
remove cover slips, 2 changes 50 ml 2X SSC (15 min at 37°C with shaking), 50 ml NTE buffer 
(500 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 8) with 20 µg/ml RNAse A for 30 min at 37°C, 2 
changes 50 ml 1X SSC (15 min at 37°C with shaking), and 50 ml Buffer 1 (100mM Tris-Hcl, 
150 mM NaCl, pH 7.5) for 5 min.  Slides were incubated with 100 µl Blocking solution (Buffer1 
with 0.1% Triton and 2% normal sheep serum) per slide at room temperature for 22 min.  The 
blocking solution was tipped off of each slide and 75 µl antibody solution (1:500 antibody 
dilution: anti-Dig antibody provided with the Roche Dig detection kit (Indianapolis, IN) and 
Buffer1 with 0.1% Triton and 1% normal sheep serum) was added to each slide and cover 
slipped.  The slides were incubated at room temperature in a humid chamber for 2 hrs.  The 
cover slips were removed and the slides were washed in 2 changes 50 ml Buffer 1 (10 min) and 
50 ml Buffer 2 (0.1M Tris-HCl, 0.1 M NaCl, and 50 mM MgCl2, pH 9.5) (10 min with shaking).  
The slides were incubated with 100 µl per slide Color Solution with Levamisole (2% NBT/BCIP 
stock solution from the Roche Dig detection kit, 97.9% Buffer 2, and 0.1% 1M Levamisole) and 
cover slips were added.  The slides were sealed with rubber cement and kept in a humid chamber 
at room temperature for 24 hrs.  The chamber was wrapped in aluminum foil to prevent light 
exposure. 
The slides were washed in 50 ml Buffer 3 (10mM Tris-HCl pH 8.1 and 1 mM EDTA) for 
5 min to remove cover slip then 50 ml water for 2 min.  The slides were mounted with Crystal 
Mount™ (Sigma, St. Louis, MO) and stored at 4°C.  
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3.14 RNA EXTRACTION 
 
 Equine testis tissue samples were processed for RNA extraction.  One sample was from 
fresh tissue that had been collected from a 2 year old stallion.  The tissue was diced and placed in 
2 ml tubes and flash frozen in liquid nitrogen.  The samples were then stored at -80°C until 
extraction.  Nine other stallion testis samples along with four other tissue samples (spleen, 
kidney, thyroid gland, and liver) were obtained from Dr. Terje Raudsepp.  These tissues had 
been diced and stored in RNAlater® (Ambion, Austin, TX ) and kept at -20°C until processing.  
Approximately 0.3 grams of each sample was ground in liquid nitrogen in ceramic 
mortars.  The powdered sample was then added to 2.0 ml TriReagent® (Ambion, Austin, TX) 
and homogenized for 3 min using a 3.0 ml syringe and 18 gauge needle.  The 2.0 ml 
TriReagent® was divided into two, 1.0 ml aliquots in 1.5 ml microcentrifuge tubes.  The samples 
were spun at 14,000xg at 4°C for 10 min.  The TriReagent® was pipetted off and added to 200 
µl BCP.  This was mixed by inverting and centrifuged same as previous.  The aqueous layer was 
pipetted off and added to 200 µl BCP with 400 µl TriReagent®.  This was again mixed and 
centrifuged as previous.  The aqueous layer was pipetted off and added to 200 µl BCP.  The tube 
was mixed and centrifuged.  The aqueous layer was pipetted off and added to 800 µl 
isopropanol, mixed by inverting, and placed at -80°C overnight.  The samples were then dried in 
an EtOH series and resuspended on ice in 50 µl H2O.  The samples were stored at -80°C.  
Aliquots were made for Nano-Drop and Bioanalyzer analyses.   
Aliquots of the total RNA samples were reserved and the rest was cleaned using RNEasy 
Clean-Up columns from Qiagen (Valencia, CA).  The samples were then quantified on the Nano-
Drop and were then DNase treated using DNA-free™ reagents (Ambion, Austin, TX).  The 
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samples were then quantified on the Nano-Drop for a final time to determine final RNA 
concentration.  The samples were stored at -80°C.     
 
 
3.15 REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION 
 
In order to synthesize cDNA for qRT-PCR, we used the High-Capacity cDNA Reverse 
Transcription kit from Ambion (Austin, TX).   The reagents were used and the guidelines from 
the kit were followed.  2 µg starting RNA from each of the 14 RNA samples listed above were 
used.  The protocol used was as listed with the reagents for a 20 µl reaction.  The primer used 
was an oligo (d)T20 primer ordered from IDT (Coralville, IA).  The reactions were incubated at 
25°C for 10 min, 37°C for 2 hrs, 70°C for 2 min.   
 The cDNA was diluted in yeast tRNA to an appropriate dilution of 1:5 for qRT-PCR 
standard curve assays.  cDNA was made again following the above guidelines for the qRT-PCR 
experiments and the products were diluted to 400 ng/µl.    
 
 
3.16 QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION 
 
 qRT-PCR experiments were conducted using the cDNA made above.  A PCR assay was 
designed using the genomic sequence obtained from the clone CH241-11J8, specific for the 
equine NMES1 gene.  An assay was also designed for equine RPS20 to be used as a reference 
gene.  An 18s assay was already available for use as a second reference gene.    
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 The assay was set-up in a 96-well plate for loading on an ABI 7900HT.  A cocktail (6.8 
µl water, 10.0 µl SYBR® greener master mix, 0.6 µl Forward Primer (10 mM), 0.6 µl Reverse 
Primer (10 mM) was made for each PCR assay.  2 µl sample cDNA was then added to each well.  
The plate was run in triplicate in order to obtain replicates.  The plate was loaded on an ABI 
7900HT and the reaction was run at 95°C for 20 sec, 40 cycles of 95°C for 1 sec, 60°C for 20 
sec, then 95°C for 15 sec, 60°C for 15 sec, and 95°C for 15 sec.  
 
 
3.17 miRNA REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION 
 
In order to quantify the expression of miR-147b in equine tissues, the TaqMan® miRNA 
RT kit (Invitrogen, Carlsbad, CA) was ordered for HSA miR-147b.  500 ng of total RNA was 
used.  The RNA samples were total RNA aliquots saved from the equine testis and other tissues 
extracted above in Section 3.16.  These samples were not column purified in order to retain the 
small RNA fraction.  The protocol provided with the reagents was modified.  RT reactions were 
run for all 10 equine testis tissues, as well as the 4 additional equine tissues for the tissue panel. 
10 µl of total RNA at a concentration of 50 ng/µl was added to a PCR tube along with 14 
µl of cocktail (0.3 µl of 100 mM dNTPs, 2.0 µl of MultiScribe
TM
 50 U/µl, 3.0  µl of 10X 
Reverse Transcription Buffer, 0.4 µl of RNase Inhibitor 20U/µl, and 8.3 µl of H2O).  6 µl of RT 
primer was added to the tube and the reactions incubated at room temperature for 30 min before 
they were loaded on an ABI 2720 and run at 30°C for 5 min, 42°C for 2 hrs, 85°C for 5 min.  
The reactions were then used as template for the miRNA qRT-PCR experiment.  
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3.18 miRNA QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN 
REACTION 
 
The RT reactions from the above section were used for the miRNA qRT-PCR assay.  We 
ordered the TaqMan® miRNA qRT-PCR kit (Invitrogen, Carlsbad, CA) and used the probe mix 
that came with the TaqMan® miRNA RT kit for HSA miR-147b.  The qRT-PCR reactions were 
carried out in 25 µl reactions in a 96-well plate.  2 µl of each RT reaction from the above section 
was loaded into a well with 23 µl of cocktail (1.3 µl of TaqMan® miRNA Assay 20X, 12.5 µl of 
TaqMan® 2X Universal PCR Master Mix, no AmpErase UNG, and 9.2 µl of H2O).  The 
reactions were run in quadruplicate to produce replicates.  The plate was loaded and run on an 
ABI 7900HT for 10 min at 95°C, then 40 cycles of: 95°C for 15 sec, 60°C for 60 sec. The data 
was then analyzed using SDS software and Microsoft Excel.   
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4. RESULTS AND DISCUSSION 
4.1 GENOMIC AND UTR SEQUENCES 
 
Screening of a BAC library was selected an efficient method for obtaining equine 
NMES1 genomic sequence data.  As detailed in Section 3.1 a PCR assay to a region of the last 
exon were used for screening the CHORI-241 equine BAC library.  As shown in Figure 1, 
superpools of the BAC library were scored for the presence of NMES1.  Clone CH241-11J8 was 
one of 2 clones that contained our gene of interest, and was selected for sequence analysis.   
Bacterial clone CH241-11J8 was cultured for genomic DNA extraction.  Retention of the 
inserted sequence of interest was verified by PCR as shown in Figure 2.  The full length genomic 
sequence was obtained by direct sequencing of this BAC by several rounds of primer-walking as 
described in Section 3.3.  At the time this analysis was begun, only a portion of the final exon 
was identified by BLAT analysis of the preliminary equine genomic sequence assembly.  Since 
the beginning of the project, version 2.0 of the assembly, equCab2, has been released. 
We aligned the genomic sequence obtained from BAC clone 11J8 to equCab2 and found 
that the proximal 5’ region of the sequence did not align with the reference assembly.  We used 
BLAST to align our obtained sequence with the equine assembly trace archive sequences 
deposited in the NCBI database.   Analysis of the trace sequences with Sequencher software 
indicated that the trace sequences had not been quality trimmed before being assembled in this 
region.   
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Figure 1 Superpools of the CHORI-241 BAC library were screened for the presence of 
the NMES1 gene by PCR.  Numbered lanes correspond to superpool wells from the CHORI 241 
plate 11.  The products were electrophoresed through a 2% agarose gel.  Positive samples from 
these numbers were used to reference a position on plate 11.  Note strong positive at number 8.  
This was at the intersection of row J and column 8.   
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When low quality sequence data are removed, or trimmed, with a quality threshold of 
Phred20, the probability of an incorrect base call is 1 in 100 or less, for a 99% accuracy rate. 
When the equine genome trace archives are trimmed to remove sequences below the Phred20 
cutoff, a gap in sequence coverage exists.  The genomic NMES1 sequence generated from BAC 
clone 11J8 partially fills this gap within the reference assembly (Figure 3).  Dark blue bases 
shown in Figure 3 are poor quality sequence.  The top row of sequence is taken from the trace 
sequence for the reference assembly; the second and fourth rows of sequence are taken from 
BAC sequence derived from this project.  The new sequence will be added to the trace archive to 
improve the equCab 2 reference assembly. 
To identify 5’ and 3’ UTR boundaries in the NMES1 mRNA, gene-specific primers were 
designed from the experimentally-derived BAC sequence for use with RLM-RACE.  RNA 
Ligase-Mediated Rapid Amplification of cDNA ends is a protocol that ligates on a 5’ adapter to 
mature capped mRNA transcripts.  Using a forward primer with the adapter sequence and a gene 
specific reverse primer, a PCR product is synthesized that can be used for sequencing.  This 
product will give you the 5’ UTR boundary for your gene of interest.  3’ RACE uses a 3’ adapter 
with a poly-T region to use with a reverse transcriptase reaction.  This yields a cDNA product of 
poly-A tail mRNA with a 3’ adapter sequence.  A gene specific forward primer is used along 
with a reverse primer from the 3’ adapter sequence for a PCR assay.  The PCR product is then  
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Figure 2 Gel electrophoresis image of PCR products from extracted BAC DNA. Samples 
are from clone CH241-58A15, CH241-11J8, and from an equine genomic DNA sample marked 
as +, as well as a No Template Control (NTC).  Clone CH241-11J8 was ultimately chosen for 
sequencing.  
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Figure 3 Screen capture of sequence analysis using Sequencher® 4.9 software.  Gap in equine reference assembly is apparent 
when the trace archives are aligned with 5’ sequence from the CH241-11J8 BAC. 
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Figure 4 Nucleotide sequence for Equus caballus NMES1 cDNA.  The predicted protein 
translation is listed below.  5’RLM-RACE primer sequence is italicized and the 3’ RACE primer 
sequence is underlined.  Arrows denote intron positions and asterisk denotes termination codon.  
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used as template for a sequencing reaction.  This protocol will yield 3’ UTR  sequence 
information.  Based on sequence data obtained from the RACE results, the equine 
NMES1 gene sequence contains an untranslated exon located upstream of the start site of 
the coding region.  This exon is predicted in many vertebrate species but experimental 
evidence has verified the existence of this 5’ UTR exon only in RNA extracted from 
human esophageal tissue.  Figure 4 illustrates the composite genomic and mRNA 
sequence obtained from these experiments. 
An alternate transcript for NMES1 has been computationally predicted for 
human, but, to our knowledge, has not been verified (ref# NM_032413.2).  RACE 
sequence results were obtained from testis RNA from 3 different stallions.  A sequence 
polymorphism was identified in one of the animals that was associated with a transcript 
variant that contained 4 additional nucleotides at the proximal 5’ end of the transcript.  It 
is not known whether this sequence difference results in any altered functionality of the 
NMES1 gene. 
 
4.2 FLUORESCENCE IN SITU HYBRIDIZATION 
 
 Fluorescence in situ hybridization (FISH) was used for verification of the 
chromosomal location of the equine NMES1 gene.  Because NMES1 was absent in early 
drafts of the equine genome sequence assembly, we chose to verify the chromosomal 
location of the gene.  By FISH, we mapped the equine NMES1 gene to a single  
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Figure 5 FISH results showing the chromosomal location of NMES1 at Eca1q23.  
The position is marked by the vertical bar to the right.  
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chromosome location, Eca 1q23.  This is shown below in Figure 5.  This result is 
consistent with the current equine genome build, equCab2.  This physical data helps to 
anchor this region of horse chromosome 1 which is currently poorly covered with clones 
in the equine radiation hybrid panel. 
 
4.3 IN SITU HYBRIDIZATION 
 
We wanted to determine the physical expression pattern of NMES1 within the 
mature equine testis.  We used in situ hybridization experiments to attempt to obtain this 
data.  We designed a 300 nt antisense probe for the coding region of the equine NMES1 
gene, along with a sense probe as a control.  This digoxigenin-labeled probe was used 
for hybridization to testis tissue sections that were collected from a 2.5 year old stallion.  
We successfully verified mRNA quality within the sections by first using a poly(d)t 
probe to hybridize to all polyadenylated RNA.  Using the NMES1-specific probe that we 
designed, we detected signal in the tunica surrounding the testis.  We used a sheep-anti-
digoxigenin antibody followed by NBT/BCIP to yield a colored precipitate on portions 
of the section where hybridization of the probe occurred.  We were unable to visualize 
any signal within the interior of the testis.  No signal was detected within the 
seminiferous tubules or the interstitial spaces between the tubules.  Typical results from 
the ISH experiments are shown in Figure 6.   
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a.        b.  
c.        d.  
e.        f.  
Figure 6 NMES1 ISH results from equine testis tissue.  a., b,. c. are of the testis 
periphery. a. is sense NMES1 probe, b. is anti-sense NMES1 probe, c. is H&E  d., e., f., 
depict seminiferous tubules within the interior of the testis. d. is sense NMES1 probe, e. 
is anti-sense NMES1 probe, f. is H&E. 
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              Why the in situ experiments did not work is unclear.  Further experiments using 
fresh frozen tissue sections and a fluorescently-labeled antibody to the digoxigenin-
labeled probe may yield more results.  Using fluorescence or radioactivity to visualize 
signal may be a more sensitive visualization system compared to a colored precipitate 
with high background color on nearby tissue.  The NMES1 mRNA is a small transcript 
and it may be extremely difficult to determine signal using a colorimetric system of 
detection.  Using fresh frozen tissue to obtain tissue sections for hybridization may also 
lead to better mRNA quality in the sections.  These procedural modifications could help 
to generate a more complete picture of NMES1 mRNA expression within the equine 
testis.  
 
4.4 QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN 
REACTION 
 
 In order to determine expression of NMES1, a qRT-PCR assay was designed.  
Expression was analyzed in four testis samples from stallions with normal fertility and 
six samples from stallions with abnormal fertility.   A qRT-PCR assay was also designed 
for equine RPS20 for use as a reference gene.  Relative expression quantities of NMES1 
were normalized to the RPS20 values.  The relative expression of NMES1 was graphed 
as shown in Figure 7 in order to visualize the differences in expression between the 
stallions with normal fertility and abnormal fertility phenotypes.   
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Figure 7 Relative quantity of NMES1 mRNA in stallion testis samples.  Samples 2N-5N 
had normal fertility, samples 1A-6A showed abnormal fertility phenotypes.  (5N =1.0) 
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4.5 miRNA QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN 
REACTION 
 
 The NMES1 gene is unusual in that it contains a miRNA within the 3’UTR.  
miR-147b has been implicated in immune response (Liu et al. 2009).  Toll like receptor 
5 has been identified as an upregulator for miR-147 (Liu et al. 2009). 
In order to determine miR-147b expression in the horse, we used the TaqMan 
miRNA RT kit and miRNA qRT-PCR assay.  The assay is specific for miR-147b.  We 
were able to use the assay for Hsa miR-147b because the mature human miRNA 
sequence is an exact match with the equine miR-147b.  We used the assay to obtain 
relative quantities of miR-147b expression in the same samples for the qRT-PCR 
experiment.  This gave us a picture of the expression levels between stallions with 
different fertility profiles, as well as the expression level in different equine tissues.   
We can determine that the expression of miR-147b in equine testis is somewhat 
variable between the two fertility groups, as well as variable within each group (Figure 
8).  The lowest expression is in horse 5N who also had the lowest expression for the 
mRNA among the fertile stallions.  Stallion 5A had the lowest miRNA expression, while 
having the second lowest mRNA expression among all of the stallions we tested. 
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Figure 8 Relative quantity of miR-147b in stallion testis samples.  Samples 2N-5N had 
normal fertility; samples 1A-6A had abnormal fertility.  5N=1.0. 
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The miR-147b expression among different tissues showed that the spleen had a 
much higher expression of the miRNA than the other tissues, even higher that testis 
(Figure 9).  This was not expected and shows that while this may not be a tissue-specific 
miRNA, the expression levels can vary from tissue to tissue.  The mRNA and miR-147b 
assays cannot be directly compared to each other, but we can see that there is an inverse 
correlation of mRNA vs. miRNA in testis versus spleen samples as shown in Figures 9 
and 10. 
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Figure 9 Relative quantity of miR-147b in an equine tissue panel.  High expression of 
miR-147b in spleen does not correspond to the relative expression of NMES1 mRNA. 
Liver = 1.0 
 
 
 
 
 
 
 
 
Figure 10  Relative quantity of NMES1 mRNA in a panel of equine tissues.  Expression 
of NMES1 in the testis sample (2N) was 9.8 times greater than in the spleen sample. 
Liver = 1.0 
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5. SUMMARY AND CONCLUSIONS 
 
This project has provided physical data for the sequence, chromosomal location, 
and tissue-specific expression quantities in stallions for the NMES1 gene.  This data also 
contributes new information about NMES1 relevant for other species.  Previously, there 
had been no experimental evidence for the 5’ and 3’ UTR boundaries.  This information 
is now available for equine testis NMES1 transcripts and can be compared against other 
tissues and species.       
 There were problems in obtaining conclusive in situ results.  This could be due to 
a number of factors and further experiments are necessary.  It could be that the transcript 
has some sort of secondary structure that makes hybridization difficult.  If the mRNA is 
kept within the nucleus, whether to be further processed into pre-miRNA or not, this 
could cause the in situ experiment to fail while still yielding quantitative data from the 
qRT-PCR experiments.          
One of the main future directions of this project is determine whether a protein is 
actually translated from the NMES1 mRNA.  Currently, there has been no experimental 
evidence that an encoded protein exists.  It is possible that the mRNA acts as a pri-
miRNA and that there is not an actual protein that is expressed.  If there is no protein, 
then it is possible that the NMES1 gene is present for the sole purpose of producing miR-
147b.   
 Also, we have qRT-PCR data for both the full-length mRNA and for miR-147b 
expression in stallion testis.  Is the ratio of mRNA to miRNA important?  Does this ratio 
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confer any information that could explain the function of NMES1?  Another question is 
whether different tissues have different mRNA variant transcripts.  cDNA sequence was 
only identified in stallion testis but it is possible that tissue-specific transcripts could 
exist.  If so, what does that say about the role of NMES1? 
 The structure of the equine NMES1 gene is unique.  Out of 680 unique human 
miRNAs identified to date, only 11 are encoded within the 3’ UTR of a gene.  NMES1 
happens to be one of those 11.  Does this rarity confer some kind of specialization?  If 
the target and function of miR-147b is identified, does this lend knowledge about a 
specific subset of miRNAs, or will the information be able to be applied to all miRNAs?   
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APPENDIX A 
 
FULL LENGTH EQUINE NMES1 GENOMIC SEQUENCE 
 
    1 TTGTCTAGAA TTAAATGAGG TTGAAACAGA GCTGGGTCTG GCCCTTTCCA CGGAACATTA 
   61 AGATGTTTCT GTTTTAACGT TAACTCATAG CTTGGACTTC AAATAGTTTA AAAATAGTTG 
  121 TTTTTAAACA ACTGAGCTTG CGCTCTTGTC TTAACTGCAG TAGCTAAGAG CAGGGAGCAG 
  181 AAAGAATAGT GATGTCGATG CCAGACAAAC CTGGGTTCTG ATTACATCTC TGCCTCTTAC 
  241 TGGCTATGTG ACTAGAGCAT CTCTGAGCCT AAATAACATA CCTTGCAAAA ATGTGGAGAA 
  301 GATTCCAGCA CAGTGTCTGG CACACAGCCG CTGATTTAAT GGAATTGTTG TTCTCCTTAT 
  361 TTCCGTGGTT TTGCAGCCGC CTGCATGCTC TGTGCAAGGC CAGGCTGCTA GCTAAGGGGC 
  421 GAGTTAAAAG GGGACCTCAA GACGAAGCCA GCCGTCGGGG TCGTCTCAGA GATAGATCTT 
  481 CTCTCGGAAG TCTTTCAAGC TGATTCTTTT TATTTCTTCT CCCCTAACCC CCTGACTTTT 
  541 TTCAACGGGA AAAATCAGGA TACCATGGGA GTTATTCTGA AAGCACTTTA CAATTTAACT 
  601 TCACTTATCA CCATATGTGC GCTACATCAC GTTTTGCAGC TTTTAACGTC ATTAGATTTA 
  661 ATTCTCATTT ACCTGCCTGC ACCTGGGAGC CTCCCCTAGG ACCCCTGGCT CGGCGGCTTC 
  721 TTTTCCGGAT CCCCTTTTAG AGGGGTTGGT TTTCACCTCT TGTTCCCAGT ACCCGACCCT 
  781 TGCAGGCGCC GGGGCTGGCC GGGAACCACC CGGAGCGCCC ACGCCCAGCC CGGGCTCGCG 
  841 CGGGGCGGCG GGTTAGAACC CGGGCGAGCG GCAGGAGGCG CCGGCGCCCG CGTTCGGCTG 
  901 CACAGCGTCT GTGGACACGG CGGCCTGCAG GGGGCGCCCG GGAGCCGGCG CCGAGCGGGG 
  961 AAAGCGAGTC AGGCAGGTCC CGTACGCCCC CTGCCCGCCC GCGTGACCCG AACGCCCGGG 
 1021 CCGGCGCTTC CGGAGCGGTT GTGGTTGGGA TATAAGGCGC CGAGGCCGAG GCGCGCTCGG 
 1081 CTCTGGGCGT TAGCTTCGTC TGCGCGGCGC CCCGCCCGTC CCCCAGGTGA GCTGCCCGCG 
 1141 GGCGCAGGCA CCGGCGAGCC GGCCCGAGGC TCGGCTTTGG AGAACGCTGG ATGGGTCGAC 
 1201 GCCTCCCAGG TTGGGTCCTA GGGGCTGAAG TTTTGATCAA TATCTTGGAC TTTTTAATTC 
 1261 TAGATTTGGC ATTCGACACT GAAGTCATCA TGAACTTTTT CCAACTCCTG AGGAAAAAGA 
 1321 AGGAGGTAAG TTTCTAAAGC AGTTGAAAAT CTCGACTGAA AATATTAATT TTAAAAGATG 
 1381 AACAGAGGGT GCAAATTTTG AAGAAAGTGT ACAATGGTAT ATAGCAATTC TGTTGTAGTT 
 1441 CACGTTGAAA CATCGGAATA TTTACTCTCC ACCTGTTCTC TGTTAGCTTA TTCCTTTGGT 
 1501 GGCGTTCATG ACCGTGGCGG CGACTGGAGC TACGTCTTTT GCTCTATATT CCCTTCGAAA 
 1561 AACCGATGTG ATGTAAGTAG GCACCATTTA TAAAAACGCT TGTGGCAGTG TTAGGTTGAC 
 1621 CTTCGGGTTA GGAAATGCAT GGTATCAGTT TCCTGGTTTT TCTCCCCAGG ATAAGAATGT 
 1681 TAAATTGTGA ACTTGGACTA GAAAACATCC TGGTATCAAA AGACTTAAAT TATGCTATGA 
 1741 ATAAAATTAG TTTGTTTCCT GTATCTAAAT ATCCTTTCAT CCATCGACCC TCCTCCTCTT 
 1801 CTCCTGCAGC GTAGTTTGAT TTTTTTTCTT TTTAAGTTTT GAAATTTAAA GTTCTTAAAT 
 1861 GGTATTTTGG GATATACATC ATCAAAATTA AATCGTTATT TTAAAGAAAT TTTTACATTT 
 1921 CAATTTGTTA GAAAGGTCTT TCCTAATTCG GTAGAGTTTA TAGATTCAGT TGTCGGCAAT 
 1981 GAACCCAATC TCAGCTCTGG ATATAGGAAG GTAAAATACC ACACATCCTG GAATATGAGC 
 2041 AAGACAAAGA CTTGAAACTG ATCTGGGCCT GGCGCAGGGC TGGAAAGGCC AGTAAAACTC 
 2101 GCCTCTGACA GAGGGACCTC GTGCCCTGCA TTTCACCACC TTACAGCCTT CAAGTCCAGC 
 2161 CCTTCTGCTG GTGCCAGAAA CCAGGGCAAG AACACTTTTG CTTGTTCTTA TCCTGGCGCT 
 2221 TCCACCCTCG TTGCTACTCA TCTTATGGGA ACATTCTCCA GTGTGGCCCA ATGAAGGGAA 
 2281 TCTGACCTCC TACCTGTAGA GGTGTTGATC CTCAATGTTT GAGCCAAACC GTGAAGCTCC 
 2341 TTGAGCGCAG ATTGATAGGA ATCTTCCCTC AATTTCAGTT AATGGATGAA TGCCTGGGTA 
 2401 GGCAGTCTGG GTCTGTCCCT GGCGTGTGTA TAGACCCAAG ATCAGAGTTG GTTTAAATTC 
 2461 GCTGACTTTG TTTAATCAGC TTTCTTTTAT TTTTAGCATT GATCGAAAAA GAAATCCAGA 
 2521 ACCTTGGGAA ACTGTGGATC CTAGTGTACC TACAAAGGTA TTGCTAAATT TGAAAGTGAT 
 2581 TTACAGTTAG CTCAAGCCTT AGCACCCTTG TCAGCAAAAT AGATGTAATA CCTTTCACTT 
 2641 TTAGGGTGCT GGTGAGTGTT AGAGAGGGTG CTATGGAGTT TGAGAGATCT AGTGCAAGTC 
 2701 CTTGTTCCAT CATTCACAGG TGATGTTAGA CAATTTGCCC TGAGACTCGC AGAATGTATA 
 2761 AAATGGGCCC AATAATAAGG CTCTACCTCA GAATTAAGAG GGTTAAAGAG GATAAAACAC 
 2821 ATAGAGCCCA TTAGTACAGT GCCTCGCCCA TAGTAAGCAG TCAAATATTA ACTTTTATCA 
 2881 TTATTATAAT ACATTATCTC ATTTTTATGC TTTATTTATC TAAAGTTAAT ATAAGGTCTA 
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 2941 TTGTGATAAA TAACAGGAGT TCCTGAAAAC AGGAATGACA TTCTCTTTAA GCAAAATTAG 
 3001 CTAATATCTA CTCATTCTTC TAAGAGTAGT GCCAAGATTT TTCACATTTT AAATATTTTG 
 3061 GAAGTAAGAA ATATTTACTC TGTTGGAATG AATACTACTT AGGTCTGTCA GGAAAGATAT 
 3121 ATATATATTT TTTTAAGTAT ACTTTTTTTG GTGAGGAAGA TTGGCCCTGA GCTAATATCT 
 3181 GTTGCCAATC TTCCTCTTTT TTTTTTTCTT TTTCTCCCCA AAGCCCCAGC ACACAGTTGT 
 3241 ATATCCTAGT TGTACGTCAT TCTAGCTCTT TTATGTGGGA TGCCACCACA GCATGGCTTG 
 3301 GTGAGTGATG TGCAGGTCTG TGCCCAGGAT CTGAACCGGC CAACCCTGGG CTGCCGAAGT 
 3361 GAAGTGTGCA AACCCAACCA CTCAGCCACA GGGCTGACCC CTATATGTTT TGGTTTTTTT 
 3421 TTTAACAAAA CTTTGTAATA ACACAGTTTG ACTTAGTGAA GGATGTTTAG GATCTTTGAA 
 3481 ACCACCTACA TCTCCTAGGT CCTGGGGTGA TAGAGAACTT GTGAGGATAA ATGAGAATCT 
 3541 CTGCATATGA GTCCTTTGAA AGTCAAGGAC TGTCCACAGC TCTCTACCTT TCCCTTATGT 
 3601 ATGACTTAGA TCCCTTGTAC CTTCACTGAG TAATTACAAT GAAGAAATTT TATCAAGAGC 
 3661 CTACTGTGTG CCAAGCCCCA CGCTAGGAGC ATTATCCATC CACTCATAAG GAGCTGATGC 
 3721 ACTTTTTTGA ACTTATAGGT CATATAAAGC CTTGGGAAGT TTAAAAATTT AGAACTTGTT 
 3781 AAGTGAAAGT GAGGTGAATG TATAATACCC TTCTCTCTGA TCCTATAACA ATTAGGAACC 
 3841 CCAGGGCTCT TTAGAGGGAT AGAGGGATAG AAGCCAACCT GTGTTACTGT TTTGTGCATG 
 3901 TTTTAGAGAT GGGAAGAGGT GATTCTTTGA CTACAAATGC TGTGGTGGTG CTTTCTTCAG 
 3961 AGGGGAGTGT GGACAGATCC CAAAAGGGGA CGAGAGGAGG AAGGACAGAT CCTAGCAAAA 
 4021 CATTTTTATT TTCCTTTTTT TTTAAAGCTT ATAACAATCA ACCAAGAATG GAAGCCCATT 
 4081 GAAGAGTTGC AGAAGGTCCG AAGGGCGACC AAATGACCAG CCCTCGCCCC TTTCTTCCCA 
 4141 AGAGTACTCT ATGAATCTAG TGGAAACACT TCTGCACAAA CTAGATTATG GGTACCAGTG 
 4201 TGCGGAAATG CTTCTGCTAC ATTTTTAGGG CTTGCCTACT TTTTCGGACT CTGGATAAGG 
 4261 AATTTTAAAG ATAGTGCAGT GATAACCACG TAGTCCAAAA ATAAGTTTCT ATGTTTATTT 
 4321 TCTTGTTGTA AGTTTGAATT TTGCATACTG AAATTTTTAT GTTTATGATG CCTGTTTTCC 
 4381 TTGAAATGTA TAAAGATTTG TAAATTAGAT TGTCTGTAAT AAAATACCAT TTGTGCAAGA 
 4441 TTTCTTAAAG ATTAGATACA TATTTAAATG GAGGAGAAAG TCTTTTTTTA TGGGAGAGAA 
 4501 ACACATTTTG AAGCATGGAG CTTCATCTTT TAAATAATAT CCAGTGCAAA TTTCTGTGTA 
 4561 AACTTTTCTT CCAAGTTTAT TCATTCACCA GAAATTTATT GAGCACCAAC TGTTAGCTGG 
 4621 GGGACTGTTT TTGTGCAGAT GAGATAAAGT AATGAATAAA ACTGAATTCT GGAGGGAGAT 
 4681 GAAGAAAAGA TGGTAATAAG TTCAGTGAGG AAAATGAAGA AGAGATGGGG TATGAGATTG 
 4741 CATAAGGATG GGTCCTGGAG GACGTGCTGG GATTCTGGTG GTGAATAGGA AGGTGGGGCG 
 4801 TGCTGAGATT GGCCCTAAAG ATGCCAAGGC TGACAATGGT GCTCCTGTGA GGGTTGGGGA 
 4861 GGGGAGGAGT CTGGGGCACC TCTTCTCTCT GGCCAGTGAT GACTCGGAGA CTGAAGGTGC 
 4921 AATCAAACCC AGCATTCCTC TGGGTTTCCC TCCTTGACTG TTCTTGAAAA TAGGACCAAG 
 4981 TAGAAAATTG CTTTTCATTA ACTTTAAAAA AAATTGAGAT ATAATTCACA TACCATAGTA 
 5041 TTCATCCATT TAAAGTGCAC AATTCTATGG TTTTCAGTAT ATTCATGATG TTTTTCAACT 
 5101 GTCTCCACCA TCTAATTCCA GAACGTTTTC ATCACCCCAA AAAGAACCCT GTAACCATAG 
 5161 CATTCATTCT GCCATTCCTG ACCCCTCTGC TTCCAGCCCC AGGCAAACAC TGATGAATTT 
 5221 TGTCTTTATG GATTTGCCTG TTCTGGATAT TTCATATAAA TGGAATCATA CATTATGTGG 
 5281 CCTCTGTGTC TGATTCCTTT CACTTAGCAT AATGTTTTCA AGATTCATCC ATGTTATGCC 
 5341 TTCTATCAGT ATATCATTCC TTTTTATGAC TAATAGTCCA TTGTATGGAT GGATGCATTT 
 5401 TATTTATCCA TCGGTTGGTG GACATTTGGA TTCTTCCCAC TTTTGGGCCA TTATGGATCA 
 5461 TGCTGTCATG AACAGCCAGG TACAAGATTT AGTGCAACCA TATATTTTCA GTTCTCTTGG 
 5521 GTATATACCT AGGTTTATTA ACTCTTTTAA ATAAAGGTGA TAGATGCTTT TTTCTTAATT 
 5581 TCTGTTTAAA TGTAATAAAA ATTTAAGAGA AGGCCTAAAT TCTTATCACC GTCAAGGCAA 
 5641 TAAAAATAAC TAGCTCCTGC TAGAGACTCG GCAAT 
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